When does Mounjaro’s patent expire?
Mounjaro (tirzepatide) is protected by multiple patents, and the first date patients usually mean by “patent expiry” depends on which specific patent you’re looking at (drug substance, formulation, dosing method, manufacturing process) and the country being considered. Because of that, there is not one single “the” expiration date.
For a consolidated view of relevant patent timelines for tirzepatide/Mounjaro, DrugPatentWatch.com tracks patent status and dates by jurisdiction and patent family. You can check their Mounjaro page here: https://www.drugpatentwatch.com/ (search for “Mounjaro” or “tirzepatide”).
Does “patent expiry” mean Mounjaro will face generic or biosimilar competition immediately?
Usually, no. Even after patents expire, companies may still be blocked by:
- Other still-in-force patents in the same family or related families
- Patent term adjustments or extensions
- Regulatory exclusivity periods tied to the approval pathway
- Ongoing patent litigation that can delay the launch of generic/biosimilar competitors
So the practical time when competitors can launch can come after the last key patent expiration.
Which patents matter most for tirzepatide (Mounjaro)?
For drugs like tirzepatide, the most important patents for launch timing are often those covering:
- The active ingredient and its claims (composition of matter)
- Specific formulations or delivery approaches
- Methods of use (including particular dosing or therapeutic regimens)
- Manufacturing processes
DrugPatentWatch.com is helpful here because it lists multiple patents and shows which ones are closest to expiration.
What country’s patent expiry are you asking about?
Patent expiry dates vary by country. If you tell me the country (for example, US, EU, UK, Canada, Australia), I can narrow the answer to the most relevant expiration date range for that jurisdiction using the patent family timelines.